Most questions about mixing a supplement with an antidepressant have no research behind them. Saffron is an exception: a handful of small randomized trials gave it to people who were already taking one. That makes this a better-studied question than most, but not a settled one. Here is what those trials found, what they were too small and too short to rule out, and what to raise with your prescriber.

This article is educational and is not medical advice. Don't start, stop or change an antidepressant or any supplement based on a web article. If you take an SSRI or any other antidepressant, talk to your prescriber or pharmacist before adding saffron. If you are thinking about suicide or are in crisis, call or text 988 in Canada or the U.S., any time. If your safety is at risk right now, call 911.

The trials that combined saffron with antidepressants

The largest enrolled 160 adults whose depressive symptoms had persisted despite antidepressant treatment. On top of their existing medication, they took either a standardized saffron extract (affron, 14 mg twice a day) or a placebo for eight weeks. On the clinician-rated depression scale, scores fell 41% with saffron and 21% with placebo. On the participants' own ratings, the two groups improved almost identically, by 27% and 26% (Lopresti 2019). The trial was funded by Pharmactive, the extract's manufacturer, and the authors themselves described the results as conflicting.

A smaller pilot gave 40 people with major depression either crocin, saffron's main pigment compound (30 mg a day), or a placebo for four weeks alongside fluoxetine, sertraline or citalopram. Self-rated depression and anxiety scores improved more with crocin (Talaei 2015). The authors list the limits themselves: a small sample, a short trial, poor medication adherence, and self-report measures only.

Across saffron research generally, the results depend on who does the scoring. A 2026 meta-analysis of 34 trials found improvements on self-rated depression and anxiety scales but not on the clinician-rated ones (Mahmoudi 2026), the reverse of the pattern in the largest add-on trial. That inconsistency is one reason saffron is not a substitute for prescribed treatment.

Saffron and antidepressant sexual side effects

Two four-week trials from the same Tehran research group tested saffron (30 mg a day) for sexual side effects in people whose depression was stable on fluoxetine. In 36 men, erectile function and intercourse satisfaction improved more than with placebo, while desire, orgasm and overall satisfaction did not differ (Modabbernia 2012). In 38 women, arousal, lubrication and pain scores improved, but desire, orgasm and satisfaction did not (Kashani 2013). Both trials were small and short. If sexual side effects are the reason you're looking at saffron, raise them with your prescriber: there are established ways to manage them, and the saffron data are an early signal rather than an answer.

What these trials can't tell you about safety

The two sexual-function trials reported side effects about as often with saffron as with placebo, and in the largest add-on trial, antidepressant side-effect scores did not get worse with saffron. That is reassuring as far as it goes, but it doesn't go far. The trials enrolled 36 to 160 people each, ran for four to eight weeks, and screened who could take part. Studies that size can't detect a problem that affects one person in a thousand, or one that appears only after months. Most of the published data also involve SSRIs, fluoxetine in particular.

Get The Signal by email. New research, grade changes and safety notes, about every two weeks. Subscribe free

The serotonin question

The theoretical worry with any mood-active supplement taken alongside an SSRI or SNRI is serotonin syndrome, a rare but potentially serious reaction to too much serotonin activity. We found no published case of serotonin syndrome involving saffron (PubMed search, October 2026). That is genuinely reassuring, but it isn't proof of safety: the combination has been studied in a few hundred people, and a rare reaction would not show up in trials this size. Our saffron profile keeps its interaction caution for that reason.

There is a second, separate question about how drugs are cleared. A 2025 review concluded that saffron and its compounds can affect several of the liver enzymes that process medicines, most notably by inhibiting CYP3A4, and called for research on whether this matters for people taking prescription drugs (Bathaei 2025). Whether it matters at supplement doses, or for any particular antidepressant, has not been studied in people.

What to ask your prescriber

  • Tell whoever prescribes your antidepressant before you start saffron, and bring the product. The trials used standardized extracts or crocin at 28 to 30 mg a day; a label that doesn't name the extract and its amount can't be matched to them.
  • Don't lower or stop your antidepressant to make room for saffron. Every trial here added saffron to ongoing treatment, and stopping an antidepressant abruptly can cause discontinuation symptoms.
  • Know the warning signs of too much serotonin: agitation or confusion, a racing heart, heavy sweating, fever, shivering, muscle twitching or stiffness, and diarrhea. Seek urgent care if you notice them, especially soon after starting something new.
  • If you have bipolar disorder, say so. Anything with a mood effect needs your prescriber's view there, and our saffron profile flags it for review.
  • If you and your prescriber agree to try saffron, ask whether to start it on its own rather than alongside other new supplements or medication changes, so that any change, good or bad, can be traced to its cause.

The bottom line

Saffron is one of the few supplements that has actually been tested alongside antidepressants. In small trials lasting up to eight weeks, adding it didn't cause obvious problems, and it may have helped some people's symptoms and sexual side effects, though the results are inconsistent and the largest trial was industry-funded. What those trials can't do is rule out rare reactions. That makes it a reasonable question to bring to your prescriber, not a change to make on your own.

References

  • Lopresti AL, Smith SJ, Hood SD, Drummond PD. "Efficacy of a standardised saffron extract (affron®) as an add-on to antidepressant medication for the treatment of persistent depressive symptoms in adults: a randomised, double-blind, placebo-controlled study." Journal of Psychopharmacology, 2019;33(11):1415–1427. PMID: 31475623.
  • Talaei A, Hassanpour Moghadam M, Sajadi Tabassi SA, Mohajeri SA. "Crocin, the main active saffron constituent, as an adjunctive treatment in major depressive disorder: a randomized, double-blind, placebo-controlled, pilot clinical trial." Journal of Affective Disorders, 2015;174:51–56. PMID: 25484177.
  • Mahmoudi R, Mohammadi-Sartang M, Servatyari K, Rafieipour N. "Effect of saffron on depression, anxiety and mood disorder: a GRADE assessed systematic review and meta-analysis of 34 randomized controlled trials." Nutritional Neuroscience, 2026;29(7):816–837. PMID: 41693488.
  • Modabbernia A, Sohrabi H, Nasehi AA, et al. "Effect of saffron on fluoxetine-induced sexual impairment in men: randomized double-blind placebo-controlled trial." Psychopharmacology, 2012;223(4):381–388. PMID: 22552758.
  • Kashani L, Raisi F, Saroukhani S, et al. "Saffron for treatment of fluoxetine-induced sexual dysfunction in women: randomized double-blind placebo-controlled study." Human Psychopharmacology, 2013;28(1):54–60. PMID: 23280545.
  • Bathaei P, Imenshahidi M, Vahdati-Mashhadian N, Hosseinzadeh H. "Effects of Crocus sativus and its active constituents on cytochrome P450: a review." Naunyn-Schmiedeberg's Archives of Pharmacology, 2025;398(9):11407–11420. PMID: 40167627.